CLICK THERAPEUTICS

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments through a smartphone. We are continuously expanding and refining our platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Rejoyn, the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, was developed by Click in collaboration with Otsuka America Pharmaceutical. Other programs under development on Click’s platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. For more information, visit www.clicktherapeutics.com.